In this Director-level role, you will partner closely with Obesity and Cardiometabolic Disorders Therapeutic Area Scientists, as well as PKDM and Early Clinical Development teams. Your leadership will be essential in designing and executing translational and precision medicine strategies for early-stage assets, guiding them from Discovery through IND-enabling studies and into first-in-human (FIH) clinical trials.
As a key translational thought leader, you will integrate cutting-edge scientific insights with strategic decision-making, steering the development of innovative therapies poised to redefine obesity and cardiometabolic care.